company background image
COLO

ColoplastCPSE:COLO B Stock Report

Market Cap

kr.216.9b

7D

3.0%

1Y

3.1%

Updated

16 Oct, 2021

Data

Company Financials +
COLO B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance5/6
Financial Health3/6
Dividends5/6

COLO B Overview

Coloplast A/S develops and markets intimate healthcare products and services worldwide.

Coloplast Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Coloplast
Historical stock prices
Current Share Pricekr.1,019.50
52 Week Highkr.855.20
52 Week Lowkr.1,187.00
Beta0.10
1 Month Change-6.51%
3 Month Change-6.85%
1 Year Change3.06%
3 Year Change58.50%
5 Year Change108.96%
Change since IPO7,878.70%

Recent News & Updates

Oct 02
Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Here's Why Coloplast (CPH:COLO B) Can Manage Its Debt Responsibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Sep 16
Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

Do Coloplast's (CPH:COLO B) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Aug 02
Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

Does This Valuation Of Coloplast A/S (CPH:COLO B) Imply Investors Are Overpaying?

How far off is Coloplast A/S ( CPH:COLO B ) from its intrinsic value? Using the most recent financial data, we'll take...

Jul 01
Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

COLO BDK Medical EquipmentDK Market
7D3.0%1.0%3.1%
1Y3.1%1.9%22.6%

Return vs Industry: COLO B exceeded the Danish Medical Equipment industry which returned 1.9% over the past year.

Return vs Market: COLO B underperformed the Danish Market which returned 22.6% over the past year.

Price Volatility

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Beta0.10
Industry Beta0.71
Market Beta1

Stable Share Price: COLO B is less volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: COLO B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
195412,500Kristian Villumsenhttps://www.coloplast.com

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags.

Coloplast Fundamentals Summary

How do Coloplast's earnings and revenue compare to its market cap?
COLO B fundamental statistics
Market Capkr.216.86b
Earnings (TTM)kr.4.56b
Revenue (TTM)kr.18.92b

47.5x

P/E Ratio

11.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COLO B income statement (TTM)
Revenuekr.18.92b
Cost of Revenuekr.5.96b
Gross Profitkr.12.95b
Expenseskr.8.39b
Earningskr.4.56b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 01, 2021

Earnings per share (EPS)21.44
Gross Margin68.47%
Net Profit Margin24.11%
Debt/Equity Ratio53.2%

How did COLO B perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

84%

Payout Ratio

Valuation

Is Coloplast undervalued compared to its fair value and its price relative to the market?

47.55x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: COLO B (DKK1019.5) is trading above our estimate of fair value (DKK981.69)

Significantly Below Fair Value: COLO B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COLO B's PE Ratio (47.5x) is in line with the Danish Medical Equipment industry average.

PE vs Market: COLO B is poor value based on its PE Ratio (47.5x) compared to the Danish market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: COLO B is poor value based on its PEG Ratio (5.6x)


Price to Book Ratio

PB vs Industry: COLO B is overvalued based on its PB Ratio (31.3x) compared to the DK Medical Equipment industry average (10.1x).


Future Growth

How is Coloplast forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

8.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLO B's forecast earnings growth (8.5% per year) is above the savings rate (0.1%).

Earnings vs Market: COLO B's earnings (8.5% per year) are forecast to grow slower than the Danish market (10% per year).

High Growth Earnings: COLO B's earnings are forecast to grow, but not significantly.

Revenue vs Market: COLO B's revenue (7.8% per year) is forecast to grow faster than the Danish market (7.3% per year).

High Growth Revenue: COLO B's revenue (7.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COLO B's Return on Equity is forecast to be very high in 3 years time (55.6%).


Past Performance

How has Coloplast performed over the past 5 years?

9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COLO B has high quality earnings.

Growing Profit Margin: COLO B's current net profit margins (24.1%) are higher than last year (21.3%).


Past Earnings Growth Analysis

Earnings Trend: COLO B's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: COLO B's earnings growth over the past year (15.5%) exceeds its 5-year average (9% per year).

Earnings vs Industry: COLO B earnings growth over the past year (15.5%) underperformed the Medical Equipment industry 103.6%.


Return on Equity

High ROE: COLO B's Return on Equity (65.8%) is considered outstanding.


Financial Health

How is Coloplast's financial position?


Financial Position Analysis

Short Term Liabilities: COLO B's short term assets (DKK6.8B) do not cover its short term liabilities (DKK7.1B).

Long Term Liabilities: COLO B's short term assets (DKK6.8B) exceed its long term liabilities (DKK1.4B).


Debt to Equity History and Analysis

Debt Level: COLO B's debt to equity ratio (53.2%) is considered high.

Reducing Debt: COLO B's debt to equity ratio has increased from 20.3% to 53.2% over the past 5 years.

Debt Coverage: COLO B's debt is well covered by operating cash flow (136.4%).

Interest Coverage: COLO B's interest payments on its debt are well covered by EBIT (324.2x coverage).


Balance Sheet


Dividend

What is Coloplast current dividend yield, its reliability and sustainability?

1.77%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: COLO B's dividend (1.77%) is higher than the bottom 25% of dividend payers in the Danish market (1.13%).

High Dividend: COLO B's dividend (1.77%) is low compared to the top 25% of dividend payers in the Danish market (3.2%).


Stability and Growth of Payments

Stable Dividend: COLO B's dividends per share have been stable in the past 10 years.

Growing Dividend: COLO B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (84%), COLO B's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: COLO B's dividends in 3 years are forecast to be covered by earnings (86% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Kristian Villumsen (51 yo)

2.83yrs

Tenure

kr.19,900,000

Compensation

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...


CEO Compensation Analysis

Compensation vs Market: Kristian's total compensation ($USD3.10M) is about average for companies of similar size in the Danish market ($USD3.37M).

Compensation vs Earnings: Kristian's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: COLO B's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: COLO B's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Coloplast A/S's employee growth, exchange listings and data sources


Key Information

  • Name: Coloplast A/S
  • Ticker: COLO B
  • Exchange: CPSE
  • Founded: 1954
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr.216.857b
  • Shares outstanding: 212.71m
  • Website: https://www.coloplast.com

Number of Employees


Location

  • Coloplast A/S
  • Holtedam 1-3
  • Humlebæk
  • Capital Region of Denmark
  • 3050
  • Denmark

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 17:02
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.